SCHEMBL16099337

SCHEMBL16099337

COc1cc(Cl)c(C(=O)Nc2ccc(-c3ccccc3)cc2)cc1[N+](=O)[O-]

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 4/20 0.61
HTT P42858 1/20 0.58
CYP3A4 P08684 2/20 0.57
TSHR P16473 2/20 0.57
ALDH1A1 P00352 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
SMO Q99835 1/20 0.53
GAA P10253 1/20 0.53
LMNA P02545 2/20 0.51
MAPT P10636 2/20 0.51
RORC P51449 2/20 0.51
TP53 P04637 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
PKM P14618 1/20 0.51
NFKB1 P19838 1/20 0.51
MAPK1 P28482 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7691380 0.93 CYP3A4 (0.65) ABCB1HTTCYP3A4TSHRALDH1A1
SCHEMBL358199 0.89 ALDH1A1 (0.65) ABCB1HTTCYP3A4TSHRALDH1A1
SCHEMBL16099082 0.81 SMO (0.57) HTTALDH1A1MEN1KMT2ASMO
SCHEMBL16098533 0.81 ALDH1A1 (0.86) ABCB1CYP3A4TSHRALDH1A1TDP1
SCHEMBL16129682 0.78 ALDH1A1 (0.74) ABCB1HTTCYP3A4TSHRALDH1A1
SCHEMBL1784674 0.76 LMNA (0.53) HTTCYP3A4TSHRALDH1A1TDP1
SCHEMBL7125062 0.76 RORC (0.85) HTTCYP3A4TSHRALDH1A1TDP1
Methyl Alcohol SCHEMBL28191422 0.76 LMNA (0.58) HTTCYP3A4TSHRALDH1A1TDP1
SCHEMBL1787152 0.75 LMNA (0.52) HTTALDH1A1TDP1MEN1KMT2A
Hydrochloric Acid SCHEMBL11778515 0.75 LMNA (0.52) HTTCYP3A4TSHRALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160052898-A1 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-25 US disclosed
US-20160052898-A1 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-25 US disclosed
EP-2976343-A2 SUBSTITUTED N-BIPHENYL-3-ACETYLAMINO-BENZAMIDES AND N-[3-(ACETYLAMINO)PHENYL]-BIPHENYL-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF THE WNT SIGNALLING PATHWAY Bayer Pharma Aktiengesellschaft (DE) 2016-01-27 EP disclosed
WO-2014147182-A2 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-25 WO disclosed
WO-2014147182-A2 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052898-A1 NOVEL COMPOUNDS AADAC, NAT1, CCNA1 ABCB1 1129/4885HTT 1838/4885CYP3A4 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.